Coherus Gets Goal Date On US Adalimumab Biosimilar

Firm Sees ‘Pent-Up Demand’ For Potential $18bn Humira Target

 
• By David Wallace
  
Calendar 2021
Coherus has received a goal date from the FDA • Source: Shutterstock

More from Biosimilars

More from Products